Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.
about
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsTrial Watch: Adoptive cell transfer for oncological indicationsPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesImmunotherapy for patients with advanced pancreatic carcinoma: A promising treatmentClinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer.Cytokine-induced killer (CIK) cells: from basic research to clinical translation.Cord blood-derived cytokine-induced killer cellular therapy plus radiation therapy for esophageal cancer: a case reportEfficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinomaIncreasing the immune activity of exosomes: the effect of miRNA-depleted exosome proteins on activating dendritic cell/cytokine-induced killer cells against pancreatic cancer.Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.Clinical applications of dendritic cells-cytokine-induced killer cells mediated immunotherapy for pancreatic cancer: an up-to-date meta-analysis.Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.T cell optimization for the treatment of pancreatic cancer.Second line treatment options for pancreatic cancer.Immunotherapy for pancreatic cancer: present and future.Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions.Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155.Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.Clinical effects of autologous cytokine-induced killer cell-based immunotherapy in the treatment of endometrial cancer: a case report and literature reviewThe Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors.Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: A meta-analysis.Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?Lentiviral delivery of CTLA-4 shRNA improves the expansion of cytokine-induced killer cells and enhances cytotoxic activity in vitro.Efficient killing of radioresistant breast cancer cells by cytokine-induced killer cells.Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity.Chemotherapy with or without autologous cytokine-induced killer cell transfusion as the first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial.Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary MalignanciesAdvanced pancreatic cancer: The standard of care and new opportunities
P2860
Q26781538-A2F1F51E-5060-4295-AD68-7C2DF2880ABCQ26785545-DE04F199-1E53-4A47-9298-0D2CA662E232Q26799714-A26FED07-9F6E-4391-9631-A239A82F794AQ28074428-96712566-2567-47FB-90BA-63363E986B01Q33427019-314CC585-8DD5-45DF-AB53-B48A35183399Q33429758-383CD08B-69AE-4B0F-A1EE-D561C67BCAEDQ36121153-4291297C-754C-4F28-803D-17A6D5B8F8D1Q36153869-16107967-4441-4A02-A0E9-DD4A5EFC7BA2Q36260887-E5F44982-17BB-4341-8561-C6297F865538Q36906098-61671914-9A67-459A-A77B-D023C06ED496Q37696350-B775715B-F8F0-45D2-B746-6498B56AB199Q38598942-3C1D72D9-98FB-40E3-910B-164D01CEC90DQ38608986-988D888A-4FE0-4378-A832-31701CF67642Q38638035-87450690-8B1F-43DF-8845-7410C5D2D556Q38640398-5D92739E-0E7C-45D5-B346-35442F49906AQ38673158-26AD5A92-14D5-429E-9AB5-54820DC1BDBBQ38783194-00E42956-CF1D-48E5-97D6-8B0F1B28D83AQ38796889-6996C680-AC67-4A92-82F2-6A33CB781477Q39208487-589A40B7-B3BD-4699-86A3-097B1A8DF441Q40289330-2E8CCFB2-218D-4C6B-B6F3-5147EFC4C5C1Q42283208-0AB58363-FAA6-4805-9AEE-7FA9CBB5EABBQ47093613-AF64AD1F-7105-424B-9F41-6B3F7CCA91F3Q47128387-6BCF250A-18FD-4898-9BEA-D9B8DCA2A6A7Q47568391-4B150C4D-041B-4E40-9C1D-3F1B125B529CQ49335229-9F033878-7F08-462B-AB5E-C353ECFA9281Q50667533-E95C203C-85E2-45FE-9626-50B78A7DA720Q52649735-F7D00BE5-FFDE-4B21-8A9B-C7EB333D0162Q52882119-EF9794C9-E453-49FD-ADD9-7A3682DF6E94Q56896166-8C387095-A2E2-4B79-93BC-AE118CA4AA68Q57822243-3F0AEBEF-E164-49E8-B997-D516E8A17DE0
P2860
Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase II clinical trial of ex ...... in advanced pancreatic cancer.
@ast
Phase II clinical trial of ex ...... in advanced pancreatic cancer.
@en
type
label
Phase II clinical trial of ex ...... in advanced pancreatic cancer.
@ast
Phase II clinical trial of ex ...... in advanced pancreatic cancer.
@en
prefLabel
Phase II clinical trial of ex ...... in advanced pancreatic cancer.
@ast
Phase II clinical trial of ex ...... in advanced pancreatic cancer.
@en
P2860
P50
P1476
Phase II clinical trial of ex ...... in advanced pancreatic cancer.
@en
P2093
Jeong Youp Park
Seung Woo Park
P2860
P2888
P304
P356
10.1007/S00262-014-1566-3
P577
2014-06-12T00:00:00Z
P5875
P6179
1047059912